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S U M M A R Y
Background: Fluoroquinolones (FQs) are used for drug-susceptible tuberculosis (TB) in patients unable
to tolerate ﬁrst-line agents. Current trials are also investigating these drugs in empiric ﬁrst-line TB
therapy, to improve outcomes and allow for shortened treatment regimens. Widespread FQ use in the
community has resulted in FQ resistance in many microorganisms, including Mycobacterium
tuberculosis. Despite this, FQ drug susceptibility testing (DST) is rarely performed in non-
multidrug-resistant TB (non-MDR-TB).
Methods: We conducted a 1-year surveillance study of FQ resistance on all MTB isolates from New
South Wales (NSW), Australia. In addition, we performed a literature review of previous studies
assessing FQ resistance in non-MDR-TB to summarize the global extent of this resistance pattern.
Results: Two (0.6%) out of 357 MTB isolates from NSW were found to be FQ-resistant. One isolate was an
MDR strain (11% of all MDR-TB). The other was isoniazid-monoresistant (0.3% of all non-MDR-TB).
Eleven studies from 10 countries had performed FQ resistance surveillance on non-MDR-TB. In the
majority of these studies, FQ resistance was found to be low (mean 1%; 95% conﬁdence interval 0.2–2%).
Conclusions: FQ resistance in non-MDR-TB is uncommon in NSW, Australia. The existing global evidence
suggests that FQ resistance remains largely conﬁned to MDR-TB strains. In the majority of TB endemic
regions, however, FQ resistance in non-MDR-TB has not been assessed. Knowledge of the prevalence of
FQ resistance in MTB is essential to guide the rational use of these drugs, including their feasibility as
ﬁrst-line agents.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Fluoroquinolones (FQs), in particular the later generation
agents such as moxiﬂoxacin and levoﬂoxacin, have potent
bactericidal activity against Mycobacterium tuberculosis (MTB)1,2
and are a key component of the treatment of multidrug-resistant
tuberculosis (MDR-TB; i.e., resistant to at least isoniazid and
rifampin).3 They are also recommended for use in drug-susceptible
TB in patients intolerant to ﬁrst-line agents.4 Current phase III
trials of FQ inclusion as ﬁrst-line agents will determine whether
this treatment strategy will improve outcomes and allow for* Corresponding author. Tel.: +61 2 98457525; fax: +61 2 98938659.
E-mail address: jho@gmp.usyd.edu.au (J. Ho).
http://dx.doi.org/10.1016/j.ijid.2014.03.1388
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).shortened treatment regimens, as suggested by preliminary
studies.5,6
Knowledge of local FQ resistance rates in MDR-TB via routine
diagnostic drug susceptibility testing (DST), or epidemiological
surveys of drug resistance, is important to guide appropriate empiric
management. Globally, out of all MDR-TB strains tested in 2012,
16.5% were found to be FQ-resistant.7 This resistance pattern is a
precursor to extensively drug-resistant TB (XDR-TB), i.e. MDR-TB
that is resistant to any FQ and at least one second-line injectable
agent (amikacin, kanamycin, or capreomycin), and confers a
signiﬁcantly poorer treatment outcome.8,9 In the majority of FQ-
resistant MDR-TB cases, FQ resistance is a consequence of
suboptimal treatment of MDR-TB with a FQ-containing regimen.10,11
In non-MDR-TB, FQ susceptibility testing is not routine and
periodic surveillance of FQ resistance remains uncommon. Whenciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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presumed but not conﬁrmed. However, recent evidence suggests
an increasing trend towards primary FQ resistance in MTB, due to
previous exposure to these drugs, before a diagnosis of TB is
made.12–14 This phenomenon has been observed not only in
regions where health care infrastructure is lacking and FQs widely
used and misused,15,16 but also in industrialized nations where
drug availability is more regulated and guideline-based prescrib-
ing is common.12,13 These ﬁndings are of direct relevance to the
choice of TB medications and support the need for wider
surveillance of FQ resistance in non-MDR- as well as MDR-TB.
Knowledge of the prevalence of FQ resistance will ensure the most
appropriate use of DST resources and the rational use of FQs in the
treatment of TB, including their feasibility as ﬁrst-line agents.
Australia has a low incidence of TB, with notiﬁcation rates
approximating 5–6 cases per 100 000 population and MDR disease
comprising about 3.5% of culture-conﬁrmed cases.17,18 The epide-
miology of TB in Australia reﬂects the global TB situation and local
immigration patterns; the majority of patients (approximately 87%)
are born, and likely acquire TB infection, overseas – most commonly
India, Nepal, Vietnam, the Philippines, and China.19 New South
Wales (NSW) is the most populous state in Australia, with over 7.2
million persons in 2011, and hosts the largest number of all
overseas-born residents in the country.20 Residents of NSW account
for over a third of all TB cases in Australia.18
In this article, we report the results of a 1-year prospective
surveillance study of FQ resistance conducted on all MTB isolates
from NSW, Australia. The primary aim of this study was to
determine whether FQ DST should be performed on all non-MDR-
TB isolates when these drugs are used for TB treatment, based on
the prevalence of FQ resistance in our setting. In particular, we felt
that the rational use of high-cost rapid molecular FQ resistance
assays,21,22 now included in many DST algorithms for MDR-TB,
when used for non-MDR-TB, should be guided by local FQ
resistance data. In addition, we reviewed previous studies of FQ
resistance in MTB in order to examine the global extent of
FQ resistance in non-MDR-TB.
2. Materials and methods
2.1. Fluoroquinolone susceptibility testing
This surveillance study was performed between February 2013
and January 2014 in the NSW Mycobacterium Reference Labora-
tory in Sydney, Australia, which conducts DST on all MTB culture
isolates from NSW. In this laboratory, susceptibility testing is
routinely performed against all ﬁrst-line TB drugs, including two
concentrations of isoniazid to detect low- and high-level isoniazid
resistance, and to second-line TB drugs in all MDR-TB isolates,
using the BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960
system (BD, Sparks, MD, USA).23 Where MDR-TB isolates are
detected or suspected, rapid detection of genotypic resistance
against FQs and aminoglycosides are also employed, prior to
phenotypic resistance detection, using Genotype MTBDRsl (Hain
Lifescience, Nehren, Germany).24 During this period of FQ
resistance surveillance, the MGIT containing the higher concen-
tration of isoniazid was replaced by one containing oﬂoxacin 2 mg/
l. Where initial low-level isoniazid resistance was detected, DST
was repeated using both concentrations of isoniazid. In isolates
where oﬂoxacin resistance was observed, DST to oﬂoxacin was
repeated and DST to moxiﬂoxacin 0.5 mg/l was also performed
using BACTEC MGIT. Minimum inhibitory concentrations (MICs) to
oﬂoxacin and moxiﬂoxacin were also examined using Sensititre
MycoTB plates (TREK Diagnostic Systems, Cleveland, OH, USA).25
The gyrA gene was sequenced for all non-MDR-TB isolates found to
be phenotypically FQ-resistant.262.2. Literature review of ﬂuoroquinolone resistance in
Mycobacterium tuberculosis
A PubMed and EMBASE database search was conducted in
December 2013 using the search terms ‘Mycobacterium tuberculo-
sis’ and ‘ﬂuoroquinolone resistance’ or ‘second-line drug resis-
tance’ to identify publications assessing the prevalence of FQ
resistance in MTB. The searches were limited to studies published
in English and within the last 15 years. Additional relevant studies
were identiﬁed by reviewing the reference lists of primary studies
and review articles identiﬁed from the database searches. Where
studies were repeated in the same region within the last 15 years,
the most recent study was included in the review. Studies that
used either phenotypic or genotypic FQ DST methods were
included, and where both were performed, the phenotypic DST
data were used. Since the objective of this review was to assess FQ
resistance in non-MDR-TB, we included cross-sectional studies
that reported the number of FQ-resistant isolates in both the entire
MTB cohort and in the MDR-TB cohort. We excluded studies where
FQ DST was performed on selected isolates or selected patients that
were not representative of the entire TB patient cohort. Corre-
sponding authors were contacted where necessary to provide
missing data or to clarify ambiguous data. Prevalence rates were
expressed as proportions with 95% conﬁdence intervals (95% CI).
Odds ratios (OR) and 95% CI were calculated to quantify the
association between FQ resistance in MDR-TB compared to that in
non-MDR-TB. All data analysis was performed using Stata 12.1
(StataCorp LP, College Station, Texas, USA). Due to the relatively
small number of studies and countries represented in this review, a
weighted pooled analysis of these data was not performed.
3. Results
3.1. Fluoroquinolone resistance in New South Wales, Australia
There were 357 non-duplicate MTB culture isolates identiﬁed
from NSW during the 1-year surveillance period. All isolates had
DST performed against ﬁrst-line TB drugs and oﬂoxacin. Nine
(2.5%) isolates were MDR, two (0.6%) rifampin-resistant (isoniazid
susceptible), 26 (7.3%) isoniazid-monoresistant, and ﬁve strains
had other resistance patterns. Oﬂoxacin resistance was detected in
two isolates (0.6% of all MTB), both of which were also
moxiﬂoxacin-resistant. One isolate was a non-XDR-TB, MDR strain
(11% of all MDR-TB) (oﬂoxacin MIC 32 mg/l, moxiﬂoxacin MIC
4 mg/l) with genotypic resistance also detected using Genotype
MDRTBsl. The one FQ-resistant isolate out of the non-MDR strains
(0.3% of all non-MDR-TB) (oﬂoxacin MIC 32 mg/l, moxiﬂoxacin MIC
8 mg/l) was also isoniazid-resistant. gyrA DNA sequencing found
no gyrA mutations in this isolate.
3.2. The global burden of ﬂuoroquinolone resistance
There were 11 studies from 10 countries identiﬁed by our
search strategy that were included in this review, including this
current surveillance study (Table 1).11,13,27–34 The studies were
carried out between 1995 and 2013. Study populations were
diverse, including TB patients from ﬁeld clinics, hospitals, and our
study which included all TB patients from a country state.
The prevalence of MDR-TB varied signiﬁcantly between studies,
ranging from 1% to 22%, mean 5% (95% CI 1–10%). All studies used
standardized DST methods and recommended critical concentra-
tions of FQ drugs. Ten studies performed DST to oﬂoxacin or
ciproﬂoxacin; four studies also performed DST to moxiﬂoxacin.
One study assessed FQ resistance using a genotypic method only.
FQ (oﬂoxacin or ciproﬂoxacin) resistance ranged from 0% to 6%,
mean 2% (95% CI 1–4%) in all MTB isolates, from 0% to 47%, mean
Table 1











Current study, 2014 Australia 2013 TB patients in New South Wales 357 9 (2.5) Automated qualitative broth-based
method (BACTEC MGIT 960)
Lai et al.,27 2011 Taiwan 2005–2010 TB patients from a tertiary referral
hospital
2693 89 (3.3) Agar proportion method
Park et al.,11 2007 Korea 1997–2005 TB patients from a medical centre
in Seoul
2788 274 (9.8) Absolute concentration method
Tessema et al.,28 2012 Ethiopia 2009 Smear-positive patients from
hospitals in Northwest Ethiopia
260 13 (5.0) DNA hybridization technology
(GenoType MTBDRsl)
van den Boogaard et al.,29
2011
Tanzania 2009–2010 Smear-positive patients from district
clinics in the Kilimanjaro region
291 3 (1.0) Automated qualitative broth-based
method (BACTEC MGIT 960)
Umubyeyi et al.,30 2007 Rwanda 2002 Smear-positive patients from
district centres
701 32 (4.6) Agar proportion method
Raﬁq et al.,31 2011 Pakistan 2006–2009 TB patients from ﬁeld clinics in
Karachi
205 45 (22.0) Agar proportion method
Casal et al.,32 2000 Spain NR TB patients from hospitals across
Spain
213 15 (7.0) Automated qualitative broth-based
method (BACTEC 460TB)
El Sahly et al.,33 2011 USA 2007–2008 TB patients in Houston, Texas 557 8 (1.4) Agar proportion method
Bozeman et al.,34 2005 USA and Canada 1995–2001 TB patients enrolled in treatment
studies with isolates susceptible
to INH and RIF
1373 0 Agar proportion method
Ginsburg et al.,13 2003 USA 1998–2002 TB patients from a teaching hospital
in Baltimore
55 1 (1.8) Automated qualitative broth-based
method (BACTEC 460TB)
MTB, Mycobacterium tuberculosis; MDR-TB, multidrug-resistant tuberculosis; NR, not reported; MGIT, Mycobacteria Growth Indicator Tube; INH, isoniazid; RIF, rifampin.
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0.2–2%) in non-MDR-TB. Overall, the odds ratio for FQ resistance in
MDR-TB compared to non-MDR-TB was 69 (95% CI 48–100).
For the countries from the Asia-Paciﬁc and East Africa region, FQ
resistance rates in non-MDR-TB were low (<1% of all non-MDR-
TB). There were three FQ resistance studies conducted in the USA
(one also included isolates from Canada). Resistance rates varied
signiﬁcantly between these studies: 0.1%, 1.3%, and 3.7% of non-
MDR-TB were oﬂoxacin- or ciproﬂoxacin-resistant. The later study
with the highest prevalence of FQ resistance included a small
sample size and was performed in a single referral hospital,
whereas the study reporting the lowest FQ resistance rate included
isolates from a large number of centres from the USA and Canada.
In this study, isolates that were resistant to isoniazid or rifampin
were excluded, which is likely to have biased FQ resistance to be
lower than that of the entire non-MDR-TB cohort. Studies from
Spain and Pakistan reported the highest proportion of non-MDR-
TB with FQ resistance: 3.0% and 4.4%, respectively (Table 2).Table 2
Summary of ﬂuoroquinolone resistance in all Mycobacterium tuberculosis, multidrug-
interval)
Reference Country FQ tested FQ-resis
n %
Current study 2014 Australia Oﬂoxacin 2 0
Moxiﬂoxacin 2 0
Lai et al.,27 2011 Taiwan Oﬂoxacin 36 1
Park et al.,11 2007 Korea Oﬂoxacin 94 3
Tessema et al.,28 2012 Ethiopia FQ gene target
(gyrA + gyrB)
0 0
van den Boogaard et al.,29 2011 Tanzania Ciproﬂoxacin 2 0
Moxiﬂoxacin 1 0
Umubyeyi et al.,30 2007 Rwanda Oﬂoxacin 4 0
Raﬁq et al.,31 2011 Pakistan Ciproﬂoxacin
or oﬂoxacin
12 5
Casal et al.,32 2000 Spain Oﬂoxacin 13 6
El Sahly et al.,33 2011 USA Oﬂoxacin 10 1
Moxiﬂoxacin 10 1
Bozeman et al.,34 2005 USA and Canada Ciproﬂoxacin 2 0
Ginsburg et al.,13 2003 USA Oﬂoxacin 2 3
Moxiﬂoxacin 1 1
FQ, ﬂuoroquinolone; MTB, Mycobacterium tuberculosis; MDR-TB, multidrug-resistant tub
a Isolates that tested intermediate were counted as resistant.Eight potentially relevant studies identiﬁed from our search
strategy were excluded from this review for the following reasons:
the inclusion of MTB isolates biased towards retreatment or
treatment failure,15 selected based on known underlying drug
resistance,35,36 selected based on known underlying patient
category (i.e., new or retreatment cases),37 insufﬁcient data to
calculate the proportion of FQ resistance in non-MDR-TB,16,38,39 or
where a more recent FQ resistance study in the same region had
been performed.40
4. Discussion
FQ resistance in MTB remains uncommon in NSW, Australia,
with only two isolates (0.6%) found to be FQ-resistant in this 1-year
surveillance study, one of which was a non-MDR-TB strain (0.3% of
all non-MDR-TB). Given that the majority of TB patients in
Australia have microbiological conﬁrmation of disease and DST
performed, we were able to accurately capture the prevalence ofresistant tuberculosis, and non-multidrug-resistant tuberculosis (95% conﬁdence
tanta MTB FQ-resistant MDR-TB FQ-resistant non-MDR-TB
 of total MTB n % of total MDR-TB n % of total non-MDR-TB
.6 (0.1–2.0) 1 11 (0.2–48) 1 0.3 (<0.01–1.6)
.6 (0.1–2.0) 1 11 (0.2–48) 1 0.3 (<0.01–1.6)
.3 (0.9–2) 28 32 (22–42) 8 0.3 (0.1–0.6)
.4 (2.7–4.1) 83 30 (25–36) 11 0.4 (0.2–0.8)
.0 (0.0–1.4) 0 0 (0–25) 0 0.0 (0.0–1.5)
.7 (<0.01–2.5) 0 0 (0–71) 2 0.7 (0.01–2.5)
.3 (<0.01–1.9) 0 0 (0–71) 1 0.3 (<0.01–1.9)
.6 (0.2–1.5) 3 9 (2–25) 1 0.1 (<0.01–0.8)
.9 (3.0–10) 5 11 (4–24) 7 4.4 (1.8–8.8)
.0 (3.3–10) 7 47 (21–73) 6 3.0 (1.1–6.5)
.8 (0.9–3.3) 3 38 (9–76) 7 1.3 (0.5–2.6)
.8 (0.9–3.3) 3 38 (9–76) 7 1.3 (0.5–2.6)
.2 (<0.01–0.6) N/A 2 0.1 (0.02–0.5)
.6 (0.4–13) 0 0 (0–98) 2 3.7 (0.5–13)
.8 (<0.01–10) 0 0 (0–98) 1 1.9 (0.04–10)
erculosis; non-MDR-TB, non-multidrug-resistant tuberculosis; N/A, not applicable.
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study to perform FQ DST by replacing the higher concentration
isoniazid containing MGIT with oﬂoxacin, resulted in essentially no
disruption to routine DST processes including minimal additional
cost or labour, and could easily be adopted by other laboratories
that employ similar DST procedures.
In Australia, the availability and use of FQ drugs is closely
regulated by the government-subsidized medication scheme,
which is aligned with the national guidelines for antimicrobial
prescribing.41 These guidelines promote the status of FQs as
reserved drugs, indicated for use in penicillin hypersensitivity, or
cases of drug resistance where other agents are not effective.42 As a
result, the use of these broad-spectrum agents in Australia has
been relatively constrained compared to other regions41 and this
has also been borne out in the low rates of FQ resistance seen in
other microorganisms.43 However, TB in Australia is predomi-
nantly a disease within the overseas-borne population, particularly
in those recently arrived. The median length of stay in Australia
prior to onset of disease is approximately 4 years (interquartile
range 2–12 years).44 Therefore FQ use in the country is unlikely to
be the main factor contributing to FQ resistance in MTB. In
countries such as India and the Philippines for example, from
where a high proportion of TB patients in Australia originate,
dramatic increases in FQ resistance have been reported, with
greater than 30% of all MTB isolates testing oﬂoxacin-resistant in
the most recent surveillance.15,16 This has been attributed to the
widespread use of FQs in these communities. These studies were
retrospective and performed on isolates likely biased towards
treatment failure, but still highlight the extent of this resistance
pattern present in these regions and the threatened empiric utility
of these agents.
There were few countries that had performed FQ resistance
studies on a representative sample of the TB population. In the
vast majority of regions where TB is endemic, the extent of this
resistance remains unknown. In most of the countries that were
represented, the prevalence of FQ resistance in non-MDR-TB was
found to be low and, unsurprisingly, considerably less than that
in MDR-TB. Several studies also examined the association
between FQ use and FQ resistance in their study population. A
positive association was found in some studies,13,33 but not in
others.11,29 These varied ﬁndings may be related to the duration
and timing of FQ exposure, and are not inconsistent with
previous reviews, which have found that the highest risk of
developing FQ-resistant MTB is with FQ use >10 days or with
multiple courses of FQs, especially when given more than 60 days
prior to TB diagnosis.14,45 These ﬁndings have been used to
support the use of a brief course of FQ to treat community-
acquired pneumonia, even in TB endemic regions, as long as TB
can be excluded rapidly.46,47 Two recent systematic reviews and
meta-analyses examining FQ use for up to 12 months prior to a
diagnosis of TB, found a clear association with FQ use and the
presence of FQ-resistant MTB (OR 2.7 and 2.8).12,48 Hence overall,
there is sufﬁcient evidence to conclude that, similar to other
microorganisms,49,50 more FQ availability and use in the
community will result in increased FQ resistance rates in MTB.
For this reason, these valuable agents should be used with
caution and consideration.
As the outcomes of current trials examining shortened
treatment regimens with FQs such as REMox and Oﬂotub are
known, the need to determine the true extent of FQ resistance in
non-MDR-TB will become even more apparent. Based on the
limited studies in this review, the low FQ resistance rates found in
non-MDR-TB suggest that the use of these drugs in ﬁrst-line
therapy is acceptable. Of note, FQ resistance rates in non-MDR-TB
were found to be considerably lower than those of ethambutol and
isoniazid (global mean resistance in new TB cases: 2.5% and 10.3%,respectively),51 the two drugs that FQs replace in these treatment-
shortening strategies.
We have demonstrated that in our setting, FQ resistance in non-
MDR-TB is exceedingly rare. Therefore, the use of rapid molecular
assays (e.g. Genotype MDRTBsl at approximately 90 Australian
dollars per test), compared to phenotypic DST with liquid culture,
is not a cost-effective strategy when FQ DST is requested on non-
MDR-TB isolates. In other regions, whether FQ DST should be
performed for all TB patients receiving these drugs, and which DST
method is most appropriate, will depend on the prevalence of FQ-
resistant MTB in each setting and the available resources to
perform this testing. Periodic surveillance of FQ resistance will be
necessary to assess drug resistance trends and guide necessary
changes to testing algorithms.
There were several limitations to this review, most importantly
the limited generalizability of these ﬁndings. The search strategy
adopted to ﬁnd studies for this review, intentionally, did not
include unpublished studies, because it was not possible to
accurately determine the nature of the study population and study
design of these reports. Moreover, several published studies were
excluded based on the inclusion of a biased cohort of MTB isolates
or incomplete data. We aimed to include studies that were
representative of the TB population in the region studied, and this
therefore limited the number of studies eligible for inclusion in the
review. Several studies used oﬂoxacin or ciproﬂoxacin for DST,
which would have overestimated the prevalence of resistance to
more potent FQs such as moxiﬂoxacin and levoﬂoxacin; these have
lower MICs, higher bactericidal activity, and superior clinical
outcomes.52,53 As these more effective FQs are increasingly used
for TB treatment, the FQ choice for DST will need to be modiﬁed
accordingly. Conversely, studies that employed purely genotypic
DST methods would have likely underestimated the prevalence
of FQ resistance.21 This review did not examine FQ resistance
rates in new compared to retreatment TB cases, however in most
low-resource, TB endemic settings, the outcome of such a review
would be highly informative for decisions regarding necessary DST
and empiric TB treatment.
In summary, we have found that FQ resistance in non-MDR-TB
in NSW, Australia is uncommon. Knowledge of the global extent of
this resistance pattern is currently hampered by the absence of
surveillance studies in the majority of regions where TB is endemic.
The existing global evidence suggests that FQ resistance in MTB
remains largely conﬁned to MDR strains. Periodic surveillance of
FQ resistance in MTB is integral to the rational and cost-effective
use of FQ susceptibility testing and ascertaining their feasibility as
empiric ﬁrst-line agents.
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